Literature DB >> 9813619

Zeta potential measurement and particle size analysis for a better understanding of urinary inhibitors of calcium oxalate crystallization.

L C Cao1, G Deng, E R Boevé, W C de Bruijn, R de Water, C F Verkoelen, J C Romijn, F H Schröder.   

Abstract

To better understand urinary inhibitors of calcium oxalate crystallization, both zeta potential measurement and particle size analysis were chosen to illustrate: (1) the potential therapeutic efficacy of G872, a semi-synthetic sulfated polysaccharide, in stone prevention; and (2) the relative contribution of various urinary fractions ¿e.g., ultrafiltered urine (UFU), Tamm-Horsfall protein (THP), urinary polyanions precipitated with cetylpyridinium chloride (CPC), urinary macromolecular substances with different concentration ratios (UMS10,50,90 and UMS'10,50,90) and THP-free urine (THPFU)¿ to total urinary inhibitory activity. The results showed: (1) addition of G872 significantly enhances urinary inhibitory activity and negative zeta potential values; (2) re-addition of the CPC to UFU completely restores urinary inhibitory activity; and (3) artificial urines prepared by mixing UMS'10,50,90 from THPFU with UFU differed in inhibitory activity from that prepared by mixing UMS10,50,90 from a pooled normal urine with UFU. Based on these experimental results, the following speculations can be made: (1) normal human urines are considered to be a protective colloidal system; (2) urinary inhibitory activity originates mainly from CPC and/or UMS; (3) normal THP is a protective material to maintain urinary inhibitory activity; and (4) mutual interaction between urinary inhibitors may change the total urinary inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9813619

Source DB:  PubMed          Journal:  Scanning Microsc        ISSN: 0891-7035


  3 in total

1.  Calcium oxalate monohydrate aggregation induced by aggregation of desialylated Tamm-Horsfall protein.

Authors:  Pragasam Viswanathan; Jeffrey D Rimer; Ann M Kolbach; Michael D Ward; Jack G Kleinman; Jeffrey A Wesson
Journal:  Urol Res       Date:  2011-01-13

2.  Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.

Authors:  Luigi Sinigaglia; Massimo Varenna; Silvia Casari
Journal:  Clin Cases Miner Bone Metab       Date:  2007-01

3.  Exploring calcium oxalate crystallization: a constant composition approach.

Authors:  Ann M Kolbach-Mandel; Jack G Kleinman; Jeffrey A Wesson
Journal:  Urolithiasis       Date:  2015-05-28       Impact factor: 3.436

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.